A Phase 2 interventional study of tamsulosin hydrochloride in Bladder, Neurogenic, sponsored by Boehringer Ingelheim. Completed at 72 sites in 14 countries. Open to participants aged 2 Years to 16 Years. Per ClinicalTrials.gov, last updated 2016-02-17.
Sponsored by Boehringer Ingelheim · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 81 studies in Urinary Bladder, Neurogenic with a site in United States — 21 open to participants now, 29 under way, 1 of them phase 3. Urinary Bladder, Neurogenic · United States.
Among the 81 studies in Urinary Bladder, Neurogenic with a site in United States, this one is the 8th largest by enrollment of the 64 interventional ones that give a count, is one of 3 that started in 2006, is one of 10 in phase 2, and was the 1st registered.
191 studies on the registry are indexed under Urinary Bladder, Neurogenic; 40 are open to participants now.
Browse Urinary Bladder, Neurogenic studies →21 of the 81 studies in Urinary Bladder, Neurogenic with a site in United States are open now. Recruiting first, the newest first:
The University of Texas Health Science Center, Houston · Sites in United States
Ages 18–75
University of Texas Southwestern Medical Center · Sites in United States
Ages 8–18
Medstar Health Research Institute · Sites in United States
Ages 18+
Medstar Health Research Institute · Sites in United States
Ages 18+
Barbara Trautner · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 25 Urinary Bladder, Neurogenic studies recruiting now, 11 (44%) set no upper age limit and 9 (36%) stop at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.
This study: 2 Years to 16 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
81 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 15 · Phase 3 8 · Phase 4 6
First in 2006; this study’s year is marked. 3 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 143 is above the median of 40 across 126 interventional studies indexed under Urinary Bladder, Neurogenic.
Median enrollment 30 across the 64 interventional studies, 72 across the 17 observational. Of the 44 that completed or were terminated, 25 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 81 have an industry lead sponsor. The 10 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Boehringer Ingelheim has 2 studies filed under Urinary Bladder, Neurogenic — fewer than ten, so there is no comparison to draw.
11 of the studies in Urinary Bladder, Neurogenic with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03952299Phase 3University of California, DavisOxybutynin for Post-surgical Bladder Pain and Urgency | 2026-12-31 |
| NCT07387315TriHealth Inc.A Randomized, Placebo-controlled Trial of Nitrous Oxide During In-office Bladder Botox Injections | 2026-11 |
| NCT04128709Christopher CooperMeasurement of Bladder Pressure With a Novel External Device (Cystomanometer) - Home Use | 2026-12 |
| NCT03456089Christopher CooperMeasurement of Bladder Pressure With a Novel External Device, Comparison to Urodynamics Testing | 2026-12-30 |
| NCT06337942University of California, Los AngelesDeceased Donor Bladder or Combined Kidney-bladder Transplantation: a Phase 0 First-in-human Study | 2027-01 |
Add all 11 to your calendar (.ics) → With an account.
Among the 81 studies in Urinary Bladder, Neurogenic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Aims of this study is to characterize the pharmacokinetic/pharmacodynamic profile and evaluate the safety, efficacy and tolerability, of tamsulosin hydrochloride as treatment in children with a neuropathic bladder, over the course of 12 months of active treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: tamsulosin hydrochloride
Drug: tamsulosin hydrochloride
Drug: tamsulosin hydrochloride
oral
Percentage of LPP Responders for Group D-Denovo and Group D-527.51 Rollover
Group D-Denovo: Leak point pressure (LPP) Response at(response defined as a subject who achieves an LPP pressure \<40 cm H2O) at the end of treatment based on two confirmatory values. Group D-527.51 Rollover: Leak point pressure (LPP) Response at (response defined as a subject who achieves an LPP pressure \<40 cm H2O) last value of the treatment based on two confirmatory values. The last value on treatment included any final value prior to discontinuation of treatment, regardless of the length of treatment. Detrusor leak point pressure (LPP) recorded in cm H2O which was obtained using a standard urodynamic technique, a cystometrogram. Descriptive statistics were used to assess this endpoint. This Outcome Measure was only pre-specified for Group D-Denovo and Group D-527.51 Rollover subjects, so results of these two groups are provided.
Time frame: Group D-Denovo: Week 52. Group D-527.51 Rollover: Week 1, Week 2, Week 3 and Week 4 prior to dose administration and Week9 (optional), Week 13 (additional), Week 26 (optional) and Week 52 after drug administration.
Number of LPP Responders at Each Visit Over Time (Classified by Last Value on Treatment) for Group D-527.51 Rollover.
Number of Leak point pressure (LPP) Responders at each visit (week) over time (classified by last value on treatment). Due to the early termination of the study, most of the LPP assessments were conducted within Weeks 1-9 of treatment. Summary of LPP response rates provided over time.The subjects are classified according to the treatment they were receiving at the last value on treatment. Therefore, no assumptions can be made regarding what dose they were receiving at a particular time point. LD: Low Dose, MD: Medium Dose and HD: High Dose This Outcome Measure was only pre-specified for Group D-527.51 Rollover subjects, so results of this group is provided.
Time frame: Week 1 (Visit 3) , Week 2 (Visit 4) , Week 3 (Visit 5) and Week 4 (Visit 6) prior to dose administration and Week 9 (Visit 7) (optional), Week 13 (Visit 8) (additional), Week 26 (Visit 9) (optional) and Week 52 (Visit 11) after drug administration.
Early Responders Who Maintained Their LPP Below 40 cm H2O During the Study for Group D-Denovo and Group D-527.51 Rollover
Early responders who maintained their detrusor leak point pressure (LPP) below 40 cm H2O during the study. Timeframe for Group D-Denovo: Low dose: Week 1, 3 \& 4 prior to dose and Week 2, 9 \& 26 (optional), 13(additional) \& 52 post dose. Medium dose: Week 1, 2 \& 4 prior to dose and Week 3, 9(optional), 13(additional), 26 (optional) \& 52 post dose. High dose: Week 1, 2 \& 3 prior to dose administration and Week 4, 9(optional), 13(additional), 26 (optional) \& 52 post dose. Group D-527.51 Rollover: Week 1, 2,3 \& 4 prior to dose and Week 9 \&26 (optional),13 (additional) \& 52 post dose. This Outcome Measure was only pre-specified for Group D-Denovo and Group D-527.51 Rollover subjects, However this endpoint was not analysed for Group D-527.51 Rollover as very limited data were collected due to early termination of the study \& no alternative endpoint was defined in the Group D-527.51 rollover, so only the results for Group D-Denovo is provided.
Time frame: Week 1 to Week 52 (Time frame for all weeks are described study wise in the Description).
Change From Baseline in LPP for Group D-527.51 Rollover
Median change from baseline in detrusor leak point pressure (LPP) by treatment group (subjects are classified according to the treatment they were taking at end of treatment) and week. Baseline assessments were obtained from trial 527.51 for Group D-527.51 Rollover. The results from Week 1 were reported because there were very few subjects who reported data at subsequent visits due to the termination of the trial. This Outcome Measure was only pre-specified for Group D-527.51 Rollover subjects, so results of this group is provided.
Time frame: Baseline and week 1
Percent Change From Baseline in LPP for Group D-527.51 Rollover
Percent change from baseline in actual detrusor leak point pressure (LPP) by treatment group (subjects are classified according to the treatment they were taking at end of treatment) and Week. Baseline assessments were obtained from trial 527.51 for Group D-527.51 Rollover. The results from Week 1 were reported because there were very few subjects who reported data at subsequent visits due to the termination of the trial. This Outcome Measure was only pre-specified for Group D-527.51 Rollover subjects, so results of this group is provided.
Time frame: Baseline and Week 1
Response Defined as Stabilization or Improvement of Hydroureter Measured by Renal Ultrasound Compared to Baseline for Group D-Denovo and Group D-527.51 Rollover
Response defined as stabilization or improvement of hydroureter measured by renal ultrasound compared to baseline by treatment group (subjects are classified according to the treatment they were taking at Week 52 or end of treatment) at week 52 for Group D-Denovo and (subjects are classified according to the treatment they were taking at the end of treatment) at last value on treatment for Group D-527.51 Rollover. Baseline assessments were obtained from trial 527.51 for Group D-527.51 Rollover. The overall treatment duration was not sufficient to reach any meaningful conclusions regarding improvement or stabilization of hydroureter in the Group D-527.51 Rollover. Hydroureter response is defined as improvement or stabilization based upon the presence or absence of hydroureter at end of treatment compared to baseline. This Outcome Measure was only pre-specified for Group D-Denovo and Group D-527.51 Rollover subjects, so results of these two groups are provided.
Time frame: Group D-Denovo: Baseline and Week 52. Group D-527.51 Rollover: Baseline, Week 26 and Week 52.
Response Defined as Stabilization or Improvement of Hydronephrosis Measured by Renal Ultrasound Compared to Baseline for Group D-Denovo and Group D-527.51 Rollover
Response defined as stabilization or improvement of hydronephrosis measured by renal ultrasound compared to baseline by treatment group (subjects are classified according to the treatment they were taking at Week 52 or end of treatment) at week 52 for Group D-Denovo and (subjects are classified according to the treatment they were taking at the end of treatment) at last value on treatment for Group D-527.51 Rollover. Baseline assessments were obtained from trial 527.51 for Group D-527.51 Rollover. The overall treatment duration was not sufficient to reach any meaningful conclusions regarding improvement or stabilization of hydronephrosis in the Group D-527.51 Rollover. Hydronephrosis response is defined as an improvement or stabilization based upon ultrasound grading at the end of the study. The lower or same grade at end of treatment compared to baseline is considered an improvement or stabilization.
Time frame: Group D-Denovo: Baseline and Week 52. Group D-527.51 Rollover: Baseline, Week 26 and Week 52.
LPP Response at Any Time During the Trial for Group D-Denovo and Group D-527.51 Rollover
Response rates of LPP responders (2 LPP values \< 40 cm H2O) at any time during the trial by treatment group. Timeframe for Group D-Denovo: Low dose: Week 1, 3 \& 4 prior to dose and Week 2, 9 \& 26 (optional), 13(additional) \& 52 post dose. Medium dose: Week 1, 2 \& 4 prior to dose and Week 3, 9(optional), 13(additional), 26 (optional) \& 52 post dose. High dose: Week 1, 2 \& 3 prior to dose administration and Week 4, 9(optional), 13(additional), 26 (optional) \& 52 post dose. Group D-527.51 Rollover: Week 1, 2, 3 \& 4 prior to dose and Week 9 \&26 (optional),13 (additional) \& 52 post dose. This Outcome Measure was only pre-specified for Group D-Denovo and Group D-527.51 Rollover subjects, so results of these two groups are provided.
Time frame: Week 1 to Week 52 (described study wise in the Description).
Number of Participants With Clinically Relevant Abnormalities for Physical Examination, Vital Signs/Orthostatic Testing, Electrocardiogram (ECG), Laboratory Values,Urinalysis,Occurence of Adverse Events & Cognitive Testing for Group D-527.51 Rollover
Number of participants with Clinically Relevant Abnormalities for Physical Examination, Vital Signs/Orthostatic testing, Electrocardiogram (ECG), Laboratory Values, Urinalysis, Occurence of Adverse events and Cognitive Testing. Relevant findings or worsening of baseline conditions were reported as adverse events. Below mentioned result are the number of subjects who had the clinical relevant abnormalities for the preferred term 'Hepatic enzyme increased'. This Outcome Measure was only pre-specified for Group D-527.51 Rollover subjects, so results of this group is provided.
Time frame: From first drug administration until 28 days after last study drug administration, upto 395 days
Number of Participants With Clinically Relevant Abnormalities for Physical Examination, Vital Signs/Orthostatic Testing, Electrocardiogram (ECG), Laboratory Values, Urinalysis, Occurence of Adverse Events and Cognitive Testing for Group D-Denovo
Number of participants with Clinically Relevant Abnormalities for Physical Examination, Vital Signs/Orthostatic testing, Electrocardiogram (ECG), Laboratory Values, Urinalysis, Occurence of Adverse events and Cognitive Testing. Relevant findings or worsening of baseline conditions were reported as adverse events. Subjects who experienced orthostatic hypotension during orthostatic testing were reported as adverse events. This Outcome Measure was only pre-specified for Group D-Denovo, so results of this group is provided.
Time frame: From first drug administration until 28 days after last study drug administration, upto 450 days
Vision Testing for Group D-Denovo
Number of subjects with a change from baseline in visual acuity by treatment group (subjects are classified according to the treatment they were taking at Week 52 or end of treatment). They were analysed based on the below mentioned category in both the Eyes: 1) No Change 2) Decrease in visual acuity 3) Increase in visual acuity 4) Missing. Missing includes subjects with no baseline exam and subjects with exam scores missing. This Outcome Measure was only pre-specified for Group D-Denovo subjects, so results of this group is provided.
Time frame: Baseline, Week 26 and Week 52.
Vision Testing for Group D-527.51 Rollover
Number of subjects with a change from baseline in visual acuity by treatment group (subjects are classified according to the treatment they were taking at end of treatment). They were analysed based on the below mentioned category in both the Eyes: 1) No Change 2) Decrease in visual acuity 3) Increase in visual acuity 4) Missing. Missing includes subjects with no baseline exam and subjects with exam scores missing. This Outcome Measure was only pre-specified for Group D-527.51 Rollover subjects, so results of this group is provided.
Time frame: Baseline and Week 52
Cmax,1
Maximum measured concentration of the analyte in plasma following the first dose, Cmax,1. This Outcome Measure was only pre-specified for PK Study- single dose group subjects, so results of this group is provided.
Time frame: -0.25h prior to dose and 2h, 4h, 6h and 8h after the drug administration.
Tmax, 1
Time from dosing to maximum measured concentration of the analyte in plasma after administration of the first dose, tmax, 1. This Outcome Measure was only pre-specified for PK Study- single dose group subjects, so results of this group is provided.
Time frame: -0.25h prior to dose and 2h, 4h, 6h and 8h after the drug administration.
Cmax, 1 ,DW ,Norm
Dose- and weight-normalized Cmax,1 (Cmax,1,DW,norm). Weight normalization of Cmax,1 was performed by dividing the respective quantities by the reciprocal of body weight in kg. This Outcome Measure was only pre-specified for PK Study- single dose group subjects, so results of this group is provided.
Time frame: -0.25h prior to dose and 2h, 4h, 6h and 8h after the drug administration.
Cpre,ss
Pre-dose concentration of the analyte in plasma at steady state immediately before administration of the next dose, Cpre,ss. This Outcome Measure was only pre-specified for PK Study- steady state group subjects, so results of this group is provided.
Time frame: -0.25h prior to dose and 2h, 4h, 6h, 8h, 10h, 24h and 33h after the drug administration.
Cmax,ss
Maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ, Cmax,ss. This Outcome Measure was only pre-specified for PK Study- steady state group subjects, so results of this group is provided.
Time frame: -0.25h prior to dose and 2h, 4h, 6h, 8h, 10h, 24h and 33h after the drug administration.
Cmax,ss, DW, Norm
Dose- and weight-normalized for Cmax,ss, Cmax,ss, DW, norm. Weight normalization of Cmax,ss was performed by dividing the respective quantities by the reciprocal of body weight in kg. This Outcome Measure was only pre-specified for PK Study- steady state group subjects, so results of this group is provided.
Time frame: -0.25h prior to dose and 2h, 4h, 6h, 8h, 10h, 24h and 33h after the drug administration.
Cmin,ss
Minimum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ, Cmin,ss. This Outcome Measure was only pre-specified for PK Study- steady state group subjects, so results of this group is provided.
Time frame: -0.25h prior to dose and 2h, 4h, 6h, 8h, 10h, 24h and 33h after the drug administration.
Tmax,ss
Time from last dosing to maximum concentration of the analyte in plasma at steady state over a uniform dosing interval τ, tmax,ss. This Outcome Measure was only pre-specified for PK Study- steady state group subjects, so results of this group is provided.
Time frame: -0.25h prior to dose and 2h, 4h, 6h, 8h, 10h, 24h and 33h after the drug administration.
AUCτ,ss
Area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval τ , AUCτ,ss. This Outcome Measure was only pre-specified for PK Study- steady state group subjects, so results of this group is provided.
Time frame: -0.25h prior to dose and 2h, 4h, 6h, 8h, 10h, 24h and 33h after the drug administration.
AUCτ ,ss ,DW ,Norm
Dose- and weight-normalized of AUCτ ,ss ( AUCτ ,ss ,DW ,norm). Weight normalization of AUCτ,ss was performed by dividing the respective quantities by the reciprocal of body weight in kg. This Outcome Measure was only pre-specified for PK Study- steady state group subjects, so results of this group is provided.
Time frame: -0.25h prior to dose and 2h, 4h, 6h, 8h, 10h, 24h and 33h after the drug administration.
λz,ss
Terminal rate constant of the analyte in plasma at steady state, λz,ss. This Outcome Measure was only pre-specified for PK Study- steady state group subjects, so results of this group is provided.
Time frame: -0.25h prior to dose and 2h, 4h, 6h, 8h, 10h, 24h and 33h after the drug administration.
t1/2,ss
Terminal half-life of the analyte in plasma at steady state, t1/2,ss. This Outcome Measure was only pre-specified for PK Study- steady state group subjects, so results of this group is provided.
Time frame: -0.25h prior to dose and 2h, 4h, 6h, 8h, 10h, 24h and 33h after the drug administration.
MRTpo,ss
Mean residence time of the analyte in the body at steady state after oral administration,MRTpo,ss. This Outcome Measure was only pre-specified for PK Study- steady state group subjects, so results of this group is provided.
Time frame: -0.25h prior to dose and 2h, 4h, 6h, 8h, 10h, 24h and 33h after the drug administration.
CL/F,ss,W,Norm
Weight-normalized CL/F,ss (apparent clearance of the analyte in the plasma at steady state after extravascular multiple dose administration), CL/F,ss,W,norm. Weight-normalized CL/F,ss was calculated by dividing the respective quantities by body weight in kg. This Outcome Measure was only pre-specified for PK Study- steady state group subjects, so results of this group is provided.
Time frame: -0.25h prior to dose and 2h, 4h, 6h, 8h, 10h, 24h and 33h after the drug administration.
Vz/F,ss,W,Norm
Weight-normalized Vz/F,ss (apparent volume of distribution during the terminal phase λz at steady state following extravascular administration), Vz/F,ss,W,norm. Weight-normalized VzF,ss was calculated by dividing the respective quantities by body weight in kg. This Outcome Measure was only pre-specified for PK Study- steady state group subjects, so results of this group is provided.
Time frame: -0.25h prior to dose and 2h, 4h, 6h, 8h, 10h, 24h and 33h after the drug administration.
RA,Cmax
The accumulation ratio was calculated from the patients who were randomised to the low dose group and for whom both parameters at first dose and steady state dose were available. Accumulation ratios of tamsulosin HCl in plasma at steady state after multiple dose administration over a uniform dosing interval τ, expressed as ratio of Cmax at steady state and after single dose. The accumulation ratio RA,Cmax was calculated as: Cmax,ss/Cmax,1. This Outcome Measure was only pre-specified for PK Study- steady state group subjects, so results from this group is provided.
Time frame: -0.25h prior to dose and 2h, 4h, 6h, 8h, 10h, 24h and 33h after the drug administration.
This trial has 3 different Data base locks (DBLs) based on 3 separate populations PK/PD, Group D-Denovo \& Group D-527.51 Rollover. For population PK/PD the DBL date was 18July2007, Group D-Denovo the DBL date was 23Jan2009 \& Group D-527.51 Rollover the DBL date was 11Sep2009.
| Milestone | Tamsulosin - Low Dose Level (PK Study) | Tamsulosin - Medium Dose Level (PK Study) | Tamsulosin - High Dose Level (PK Study) | Tamsulosin - Low Dose Level (Group D-Denovo) | Tamsulosin - Medium Dose Level (Group D-Denovo) | Tamsulosin - High Dose Level (Group D-Denovo) | Tamsulosin - Low Dose Level (Group D-527.51 Rollover) | Tamsulosin - Medium Dose Level (Group D-527.51 Rollover) | Tamsulosin - High Dose Level (Group D-527.51 Rollover) |
|---|---|---|---|---|---|---|---|---|---|
| Started | 10 | 10 | 11 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 10 | 9 | 10 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Not treated | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Tamsulosin - Low Dose Level (PK Study) | Tamsulosin - Medium Dose Level (PK Study) | Tamsulosin - High Dose Level (PK Study) | Tamsulosin - Low Dose Level (Group D-Denovo) | Tamsulosin - Medium Dose Level (Group D-Denovo) | Tamsulosin - High Dose Level (Group D-Denovo) | Tamsulosin - Low Dose Level (Group D-527.51 Rollover) | Tamsulosin - Medium Dose Level (Group D-527.51 Rollover) | Tamsulosin - High Dose Level (Group D-527.51 Rollover) |
|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 29 | 21 | 37 | 54 | 13 | 29 |
| Pk study subjects entered group d-denovo | 0 | 0 | 0 | 7 | 5 | 18 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 27 | 16 | 30 | 1 | 1 | 0 |
| Not completed | 0 | 0 | 0 | 2 | 5 | 7 | 53 | 12 | 29 |
| Withdrew: Adverse event | 0 | 0 | 0 | 2 | 4 | 0 | 0 | 1 | 1 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 1 | 3 | 0 | 0 | 0 |
| Withdrew: Other reason not defined above | 0 | 0 | 0 | 0 | 0 | 3 | 53 | 11 | 28 |
Group D-Denovo: Leak point pressure (LPP) Response at(response defined as a subject who achieves an LPP pressure \<40 cm H2O) at the end of treatment based on two confirmatory values. Group D-527.51 Rollover: Leak point pressure (LPP) Response at (response defined as a subject who achieves an LPP pressure \<40 cm H2O) last value of the treatment based on two confirmatory values. The last value on treatment included any final value prior to discontinuation of treatment, regardless of the length of treatment. Detrusor leak point pressure (LPP) recorded in cm H2O which was obtained using a standard urodynamic technique, a cystometrogram. Descriptive statistics were used to assess this endpoint. This Outcome Measure was only pre-specified for Group D-Denovo and Group D-527.51 Rollover subjects, so results of these two groups are provided.
| percentage of responders | Tamsulosin - Low Dose Level (Group D-Denovo) | Tamsulosin - Medium Dose Level (Group D-Denovo) | Tamsulosin - High Dose Level (Group D-Denovo) | Tamsulosin - Low Dose Level (Group D-527.51 Rollover) | Tamsulosin - Medium Dose Level (Group D-527.51 Rollover) | Tamsulosin - High Dose Level (Group D-527.51 Rollover) |
|---|---|---|---|---|---|---|
| Percentage of LPP Responders for Group D-Denovo and Group D-527.51 Rollover | 73.1 | 35.7 | 26.7 | 67.9 | 58.3 | 20.7 |
Number of Leak point pressure (LPP) Responders at each visit (week) over time (classified by last value on treatment). Due to the early termination of the study, most of the LPP assessments were conducted within Weeks 1-9 of treatment. Summary of LPP response rates provided over time.The subjects are classified according to the treatment they were receiving at the last value on treatment. Therefore, no assumptions can be made regarding what dose they were receiving at a particular time point. LD: Low Dose, MD: Medium Dose and HD: High Dose This Outcome Measure was only pre-specified for Group D-527.51 Rollover subjects, so results of this group is provided.
| Participants | Tamsulosin - Low Dose Level (Group D-527.51 Rollover) | Tamsulosin - Medium Dose Level (Group D-527.51 Rollover) | Tamsulosin - High Dose Level (Group D-527.51 Rollover) |
|---|---|---|---|
| Week 1 (N= 40 (LD), 12 (MD), 27 (HD)) | 38 | 1 | 0 |
| Week 2 (N= 2 (LD), 7 (MD), 27 (HD)) | 2 | 7 | 2 |
| Week 3 (N= 3 (LD), 0 (MD), 22 (HD)) | 2 | 0 | 5 |
| Week 4 (N= 1 (LD), 0 (MD), 3 (HD)) | 1 | 0 | 0 |
| Week 9 (N= 7 (LD), 2 (MD), 16 (HD)) | 5 | 2 | 5 |
| Week 13 (N= 4 (LD), 0 (MD), 2 (HD)) | 1 | 0 | 1 |
| Week 26 (N= 2 (LD), 0 (MD), 3 (HD)) | 1 | 0 | 1 |
| Week 52 (N= 1 (LD), 1 (MD), 0 (HD)) | 1 | 1 | 0 |
Early responders who maintained their detrusor leak point pressure (LPP) below 40 cm H2O during the study. Timeframe for Group D-Denovo: Low dose: Week 1, 3 \& 4 prior to dose and Week 2, 9 \& 26 (optional), 13(additional) \& 52 post dose. Medium dose: Week 1, 2 \& 4 prior to dose and Week 3, 9(optional), 13(additional), 26 (optional) \& 52 post dose. High dose: Week 1, 2 \& 3 prior to dose administration and Week 4, 9(optional), 13(additional), 26 (optional) \& 52 post dose. Group D-527.51 Rollover: Week 1, 2,3 \& 4 prior to dose and Week 9 \&26 (optional),13 (additional) \& 52 post dose. This Outcome Measure was only pre-specified for Group D-Denovo and Group D-527.51 Rollover subjects, However this endpoint was not analysed for Group D-527.51 Rollover as very limited data were collected due to early termination of the study \& no alternative endpoint was defined in the Group D-527.51 rollover, so only the results for Group D-Denovo is provided.
| Participants | Tamsulosin-low Dose Level (Group D-Denovo) | Tamsulosin-medium Dose Level (Group D-Denovo) | Tamsulosin - High Dose Level (Group D-Denovo) | Tamsulosin - Low Dose Level (Group D-527.51 Rollover) | Tamsulosin - Medium Dose Level (Group D-527.51 Rollover) | Tamsulosin - High Dose Level (Group D-527.51 Rollover) |
|---|---|---|---|---|---|---|
| Early Responders Who Maintained Their LPP Below 40 cm H2O During the Study for Group D-Denovo and Group D-527.51 Rollover | 17 | 5 | 3 | — | — | — |
Median change from baseline in detrusor leak point pressure (LPP) by treatment group (subjects are classified according to the treatment they were taking at end of treatment) and week. Baseline assessments were obtained from trial 527.51 for Group D-527.51 Rollover. The results from Week 1 were reported because there were very few subjects who reported data at subsequent visits due to the termination of the trial. This Outcome Measure was only pre-specified for Group D-527.51 Rollover subjects, so results of this group is provided.
| cm H2O | Tamsulosin - Low Dose Level (Group D-527.51 Rollover) | Tamsulosin - Medium Dose Level (Group D-527.51 Rollover) | Tamsulosin - High Dose Level (Group D-527.51 Rollover) |
|---|---|---|---|
| Baseline (N= 53 (LD), 12 (MD), 29(HD)) | 48.50 ± 14.47 | 48.5 ± 11.19 | 55.50 ± 24.52 |
| Week 1 - Actual (N= 39 (LD), 9 (MD),22 (HD)) | 29.00 ± 8.50 | 49.50 ± 8.30 | 64.75 ± 27.20 |
| Week 1 - Change (N= 39 (LD), 9 (MD),22 (HD)) | -25.5 ± 15.18 | -2 ± 13.68 | -1.25 ± 24.97 |
Percent change from baseline in actual detrusor leak point pressure (LPP) by treatment group (subjects are classified according to the treatment they were taking at end of treatment) and Week. Baseline assessments were obtained from trial 527.51 for Group D-527.51 Rollover. The results from Week 1 were reported because there were very few subjects who reported data at subsequent visits due to the termination of the trial. This Outcome Measure was only pre-specified for Group D-527.51 Rollover subjects, so results of this group is provided.
| percent change | Tamsulosin - Low Dose Level (Group D-527.51 Rollover) | Tamsulosin - Medium Dose Level (Group D-527.51 Rollover) | Tamsulosin - High Dose Level (Group D-527.51 Rollover) |
|---|---|---|---|
| Baseline (N= 53 (LD), 12 (MD), 29 (HD)) | 48.50 ± 14.47 | 48.50 ± 11.19 | 55.50 ± 24.52 |
| Week 1 - Actual (N= 39 (LD), 9 (MD), 22 (HD)) | 29.00 ± 8.50 | 49.50 ± 8.30 | 64.75 ± 27.20 |
| Week 1 - Change (N= 39 (LD), 9 (MD), 22 (HD)) | -48.48 ± 18.65 | -3.88 ± 22.43 | -2.71 ± 40.41 |
Response defined as stabilization or improvement of hydroureter measured by renal ultrasound compared to baseline by treatment group (subjects are classified according to the treatment they were taking at Week 52 or end of treatment) at week 52 for Group D-Denovo and (subjects are classified according to the treatment they were taking at the end of treatment) at last value on treatment for Group D-527.51 Rollover. Baseline assessments were obtained from trial 527.51 for Group D-527.51 Rollover. The overall treatment duration was not sufficient to reach any meaningful conclusions regarding improvement or stabilization of hydroureter in the Group D-527.51 Rollover. Hydroureter response is defined as improvement or stabilization based upon the presence or absence of hydroureter at end of treatment compared to baseline. This Outcome Measure was only pre-specified for Group D-Denovo and Group D-527.51 Rollover subjects, so results of these two groups are provided.
| Participants | Tamsulosin-low Dose Level (Group D-Denovo) | Tamsulosin-medium Dose Level (Group D-Denovo) | Tamsulosin - High Dose Level (Group D-Denovo) | Tamsulosin - Low Dose Level (Group D-527.51 Rollover) | Tamsulosin - Medium Dose Level (Group D-527.51 Rollover) | Tamsulosin - High Dose Level (Group D-527.51 Rollover) |
|---|---|---|---|---|---|---|
| Right Kidney | 26 | 15 | 28 | 43 | 8 | 19 |
| Left Kidney | 24 | 14 | 29 | 43 | 8 | 17 |
Response defined as stabilization or improvement of hydronephrosis measured by renal ultrasound compared to baseline by treatment group (subjects are classified according to the treatment they were taking at Week 52 or end of treatment) at week 52 for Group D-Denovo and (subjects are classified according to the treatment they were taking at the end of treatment) at last value on treatment for Group D-527.51 Rollover. Baseline assessments were obtained from trial 527.51 for Group D-527.51 Rollover. The overall treatment duration was not sufficient to reach any meaningful conclusions regarding improvement or stabilization of hydronephrosis in the Group D-527.51 Rollover. Hydronephrosis response is defined as an improvement or stabilization based upon ultrasound grading at the end of the study. The lower or same grade at end of treatment compared to baseline is considered an improvement or stabilization.
| Participants | Tamsulosin-low Dose Level (Group D-Denovo) | Tamsulosin-medium Dose Level (Group D-Denovo) | Tamsulosin - High Dose Level (Group D-Denovo) | Tamsulosin - Low Dose Level (Group D-527.51 Rollover) | Tamsulosin - Medium Dose Level (Group D-527.51 Rollover) | Tamsulosin - High Dose Level (Group D-527.51 Rollover) |
|---|---|---|---|---|---|---|
| Right Kidney | 26 | 15 | 28 | 39 | 8 | 17 |
| Left Kidney | 24 | 14 | 26 | 42 | 7 | 17 |
Response rates of LPP responders (2 LPP values \< 40 cm H2O) at any time during the trial by treatment group. Timeframe for Group D-Denovo: Low dose: Week 1, 3 \& 4 prior to dose and Week 2, 9 \& 26 (optional), 13(additional) \& 52 post dose. Medium dose: Week 1, 2 \& 4 prior to dose and Week 3, 9(optional), 13(additional), 26 (optional) \& 52 post dose. High dose: Week 1, 2 \& 3 prior to dose administration and Week 4, 9(optional), 13(additional), 26 (optional) \& 52 post dose. Group D-527.51 Rollover: Week 1, 2, 3 \& 4 prior to dose and Week 9 \&26 (optional),13 (additional) \& 52 post dose. This Outcome Measure was only pre-specified for Group D-Denovo and Group D-527.51 Rollover subjects, so results of these two groups are provided.
| participants | Tamsulosin-low Dose Level (Group D-Denovo) | Tamsulosin-medium Dose Level (Group D-Denovo) | Tamsulosin - High Dose Level (Group D-Denovo) | Tamsulosin - Low Dose Level (Group D-527.51 Rollover) | Tamsulosin - Medium Dose Level (Group D-527.51 Rollover) | Tamsulosin - High Dose Level (Group D-527.51 Rollover) |
|---|---|---|---|---|---|---|
| LPP Response at Any Time During the Trial for Group D-Denovo and Group D-527.51 Rollover | 26 | 16 | 16 | 42 | 8 | 12 |
Number of participants with Clinically Relevant Abnormalities for Physical Examination, Vital Signs/Orthostatic testing, Electrocardiogram (ECG), Laboratory Values, Urinalysis, Occurence of Adverse events and Cognitive Testing. Relevant findings or worsening of baseline conditions were reported as adverse events. Below mentioned result are the number of subjects who had the clinical relevant abnormalities for the preferred term 'Hepatic enzyme increased'. This Outcome Measure was only pre-specified for Group D-527.51 Rollover subjects, so results of this group is provided.
| Participants | Tamsulosin - Low Dose Level (Group D-527.51 Rollover) | Tamsulosin - Medium Dose Level (Group D-527.51 Rollover) | Tamsulosin - High Dose Level (Group D-527.51 Rollover) |
|---|---|---|---|
| Number of Participants With Clinically Relevant Abnormalities for Physical Examination, Vital Signs/Orthostatic Testing, Electrocardiogram (ECG), Laboratory Values,Urinalysis,Occurence of Adverse Events & Cognitive Testing for Group D-527.51 Rollover | 1 | 0 | 0 |
Number of participants with Clinically Relevant Abnormalities for Physical Examination, Vital Signs/Orthostatic testing, Electrocardiogram (ECG), Laboratory Values, Urinalysis, Occurence of Adverse events and Cognitive Testing. Relevant findings or worsening of baseline conditions were reported as adverse events. Subjects who experienced orthostatic hypotension during orthostatic testing were reported as adverse events. This Outcome Measure was only pre-specified for Group D-Denovo, so results of this group is provided.
| Participants | Tamsulosin - Low Dose Level (Group D-Denovo) | Tamsulosin - Medium Dose Level (Group D-Denovo) | Tamsulosin - High Dose Level (Group D-Denovo) |
|---|---|---|---|
| Blood urine present | 0 | 0 | 1 |
| Body temperature increased | 0 | 0 | 1 |
| Orthostatic hypotension | 1 | 3 | 0 |
Number of subjects with a change from baseline in visual acuity by treatment group (subjects are classified according to the treatment they were taking at Week 52 or end of treatment). They were analysed based on the below mentioned category in both the Eyes: 1) No Change 2) Decrease in visual acuity 3) Increase in visual acuity 4) Missing. Missing includes subjects with no baseline exam and subjects with exam scores missing. This Outcome Measure was only pre-specified for Group D-Denovo subjects, so results of this group is provided.
| Participants | Tamsulosin - Low Dose Level (Group D-Denovo) | Tamsulosin - Medium Dose Level (Group D-Denovo) | Tamsulosin - High Dose Level (Group D-Denovo) |
|---|---|---|---|
| Right Eye (Week 26) - No Change | 11 | 7 | 12 |
| Right Eye (Week 26) - Decrease in visual acuity | 8 | 1 | 8 |
| Right Eye (Week 26) - Increase in visual acuity | 8 | 4 | 11 |
| Right Eye (Week 26) - Missing | 2 | 9 | 6 |
| Left Eye (Week 26) - No Change | 11 | 6 | 19 |
| Left Eye (Week 26) - Decrease in visual acuity | 7 | 1 | 4 |
| Left Eye (Week 26) - Increase in visual acuity | 9 | 5 | 8 |
| Left Eye (Week 26) - Missing | 2 | 9 | 6 |
| Right Eye (Week 52) - No Change | 7 | 6 | 16 |
| Right Eye (Week 52) - Decrease in visual acuity | 10 | 2 | 4 |
| Right Eye (Week 52) - Increase in visual acuity | 11 | 6 | 12 |
| Right Eye (Week 52) - Missing | 1 | 7 | 5 |
| Left Eye (Week 52) - No Change | 11 | 5 | 12 |
| Left Eye (Week 52) - Decrease in visual acuity | 6 | 3 | 6 |
| Left Eye (Week 52) - Increase in visual acuity | 11 | 7 | 14 |
| Left Eye (Week 52) - Missing | 1 | 6 | 5 |
Number of subjects with a change from baseline in visual acuity by treatment group (subjects are classified according to the treatment they were taking at end of treatment). They were analysed based on the below mentioned category in both the Eyes: 1) No Change 2) Decrease in visual acuity 3) Increase in visual acuity 4) Missing. Missing includes subjects with no baseline exam and subjects with exam scores missing. This Outcome Measure was only pre-specified for Group D-527.51 Rollover subjects, so results of this group is provided.
| Participants | Tamsulosin - Low Dose Level (Group D-527.51 Rollover) | Tamsulosin - Medium Dose Level (Group D-527.51 Rollover) | Tamsulosin - High Dose Level (Group D-527.51 Rollover) |
|---|---|---|---|
| Right Eye - No Change | 32 | 10 | 12 |
| Right Eye - Decrease in visual acuity | 5 | 2 | 4 |
| Right Eye - Increase in visual acuity | 12 | 1 | 6 |
| Right Eye - Missing | 5 | 0 | 7 |
| Left Eye - No Change | 31 | 12 | 12 |
| Left Eye - Decrease in visual acuity | 8 | 1 | 3 |
| Left Eye - Increase in visual acuity | 10 | 0 | 7 |
| Left Eye - Missing | 5 | 0 | 7 |
Maximum measured concentration of the analyte in plasma following the first dose, Cmax,1. This Outcome Measure was only pre-specified for PK Study- single dose group subjects, so results of this group is provided.
| ng/mL | PK Study - Single Dose |
|---|---|
| Cmax,1 | 1.67 ± 68.80 |
Time from dosing to maximum measured concentration of the analyte in plasma after administration of the first dose, tmax, 1. This Outcome Measure was only pre-specified for PK Study- single dose group subjects, so results of this group is provided.
| hours | PK Study - Single Dose |
|---|---|
| Tmax, 1 | 6 (2 to 8) |
Dose- and weight-normalized Cmax,1 (Cmax,1,DW,norm). Weight normalization of Cmax,1 was performed by dividing the respective quantities by the reciprocal of body weight in kg. This Outcome Measure was only pre-specified for PK Study- single dose group subjects, so results of this group is provided.
| ng/mL/mg*kg | PK Study - Single Dose |
|---|---|
| Cmax, 1 ,DW ,Norm | 1120 ± 67.20 |
Pre-dose concentration of the analyte in plasma at steady state immediately before administration of the next dose, Cpre,ss. This Outcome Measure was only pre-specified for PK Study- steady state group subjects, so results of this group is provided.
| ng/mL | Tamsulosin - Low Dose Level (Steady State - PK Study) | Tamsulosin - Medium Dose Level (Steady State - PK Study) | Tamsulosin - High Dose Level (Steady State - PK Study) |
|---|---|---|---|
| Cpre,ss | 0.914 ± 159 | 1.83 ± 131 | 4.03 ± 70.60 |
Maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ, Cmax,ss. This Outcome Measure was only pre-specified for PK Study- steady state group subjects, so results of this group is provided.
| ng/mL | Tamsulosin - Low Dose Level (Steady State - PK Study) | Tamsulosin - Medium Dose Level (Steady State - PK Study) | Tamsulosin - High Dose Level (Steady State - PK Study) |
|---|---|---|---|
| Cmax,ss | 2.79 ± 59.50 | 5.02 ± 94.80 | 14.10 ± 50.30 |
Dose- and weight-normalized for Cmax,ss, Cmax,ss, DW, norm. Weight normalization of Cmax,ss was performed by dividing the respective quantities by the reciprocal of body weight in kg. This Outcome Measure was only pre-specified for PK Study- steady state group subjects, so results of this group is provided.
| ng/mL/mg*kg | Tamsulosin - Low Dose Level (Steady State - PK Study) | Tamsulosin - Medium Dose Level (Steady State - PK Study) | Tamsulosin - High Dose Level (Steady State - PK Study) |
|---|---|---|---|
| Cmax,ss, DW, Norm | 2040 ± 74.30 | 1850 ± 85.70 | 2240 ± 47.60 |
Minimum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ, Cmin,ss. This Outcome Measure was only pre-specified for PK Study- steady state group subjects, so results of this group is provided.
| ng/mL | Tamsulosin - Low Dose Level (Steady State - PK Study) | Tamsulosin - Medium Dose Level (Steady State - PK Study) | Tamsulosin - High Dose Level (Steady State - PK Study) |
|---|---|---|---|
| Cmin,ss | 0.747 ± 99.70 | 1.52 ± 130 | 4.01 ± 68.50 |
Time from last dosing to maximum concentration of the analyte in plasma at steady state over a uniform dosing interval τ, tmax,ss. This Outcome Measure was only pre-specified for PK Study- steady state group subjects, so results of this group is provided.
| hours | Tamsulosin - Low Dose Level (Steady State - PK Study) | Tamsulosin - Medium Dose Level (Steady State - PK Study) | Tamsulosin - High Dose Level (Steady State - PK Study) |
|---|---|---|---|
| Tmax,ss | 5.00 ± 99.7 | 5.92 ± 130 | 5.01 ± 68.5 |
Area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval τ , AUCτ,ss. This Outcome Measure was only pre-specified for PK Study- steady state group subjects, so results of this group is provided.
| ng*h/mL | Tamsulosin - Low Dose Level (Steady State - PK Study) | Tamsulosin - Medium Dose Level (Steady State - PK Study) | Tamsulosin - High Dose Level (Steady State - PK Study) |
|---|---|---|---|
| AUCτ,ss | 35.80 ± 75.60 | 68.20 ± 94.70 | 175.00 ± 61.00 |
Dose- and weight-normalized of AUCτ ,ss ( AUCτ ,ss ,DW ,norm). Weight normalization of AUCτ,ss was performed by dividing the respective quantities by the reciprocal of body weight in kg. This Outcome Measure was only pre-specified for PK Study- steady state group subjects, so results of this group is provided.
| ng*h/mL/mg*kg | Tamsulosin - Low Dose Level (Steady State - PK Study) | Tamsulosin - Medium Dose Level (Steady State - PK Study) | Tamsulosin - High Dose Level (Steady State - PK Study) |
|---|---|---|---|
| AUCτ ,ss ,DW ,Norm | 26100 ± 91.10 | 25200 ± 82.90 | 27700 ± 59.10 |
Terminal rate constant of the analyte in plasma at steady state, λz,ss. This Outcome Measure was only pre-specified for PK Study- steady state group subjects, so results of this group is provided.
| 1/hours | Tamsulosin - Low Dose Level (Steady State - PK Study) | Tamsulosin - Medium Dose Level (Steady State - PK Study) | Tamsulosin - High Dose Level (Steady State - PK Study) |
|---|---|---|---|
| λz,ss | 0.0589 ± 48.10 | 0.0671 ± 40.80 | 0.0496 ± 31.90 |
Terminal half-life of the analyte in plasma at steady state, t1/2,ss. This Outcome Measure was only pre-specified for PK Study- steady state group subjects, so results of this group is provided.
| hours | Tamsulosin - Low Dose Level (Steady State - PK Study) | Tamsulosin - Medium Dose Level (Steady State - PK Study) | Tamsulosin - High Dose Level (Steady State - PK Study) |
|---|---|---|---|
| t1/2,ss | 11.80 ± 48.10 | 10.30 ± 40.80 | 14.00 ± 31.90 |
Mean residence time of the analyte in the body at steady state after oral administration,MRTpo,ss. This Outcome Measure was only pre-specified for PK Study- steady state group subjects, so results of this group is provided.
| hours | Tamsulosin - Low Dose Level (Steady State - PK Study) | Tamsulosin - Medium Dose Level (Steady State - PK Study) | Tamsulosin - High Dose Level (Steady State - PK Study) |
|---|---|---|---|
| MRTpo,ss | 18.70 ± 50.50 | 17.60 ± 35.00 | 20.90 ± 23.60 |
Weight-normalized CL/F,ss (apparent clearance of the analyte in the plasma at steady state after extravascular multiple dose administration), CL/F,ss,W,norm. Weight-normalized CL/F,ss was calculated by dividing the respective quantities by body weight in kg. This Outcome Measure was only pre-specified for PK Study- steady state group subjects, so results of this group is provided.
| L/h/kg | Tamsulosin - Low Dose Level (Steady State - PK Study) | Tamsulosin - Medium Dose Level (Steady State - PK Study) | Tamsulosin - High Dose Level (Steady State - PK Study) |
|---|---|---|---|
| CL/F,ss,W,Norm | 0.0383 ± 91.10 | 0.0397 ± 82.90 | 0.0361 ± 59.10 |
Weight-normalized Vz/F,ss (apparent volume of distribution during the terminal phase λz at steady state following extravascular administration), Vz/F,ss,W,norm. Weight-normalized VzF,ss was calculated by dividing the respective quantities by body weight in kg. This Outcome Measure was only pre-specified for PK Study- steady state group subjects, so results of this group is provided.
| L/kg | Tamsulosin - Low Dose Level (Steady State - PK Study) | Tamsulosin - Medium Dose Level (Steady State - PK Study) | Tamsulosin - High Dose Level (Steady State - PK Study) |
|---|---|---|---|
| Vz/F,ss,W,Norm | 0.65 ± 83.80 | 0.591 ± 103.00 | 0.729 ± 96.00 |
The accumulation ratio was calculated from the patients who were randomised to the low dose group and for whom both parameters at first dose and steady state dose were available. Accumulation ratios of tamsulosin HCl in plasma at steady state after multiple dose administration over a uniform dosing interval τ, expressed as ratio of Cmax at steady state and after single dose. The accumulation ratio RA,Cmax was calculated as: Cmax,ss/Cmax,1. This Outcome Measure was only pre-specified for PK Study- steady state group subjects, so results from this group is provided.
| Ratio | Tamsulosin - Low Dose Level (Steady State - PK Study) |
|---|---|
| RA,Cmax | 1.58 ± 65.20 |
Collected over From first drug administration until 28 days after last study drug administration, upto 80 days (Steady State - PK study), upto 450 days (Group D-Denovo) and upto 395 days (Group D-527.51 Rollover).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tamsulosin - Low Dose Level (Steady State - PK Study) | — | 0/10 (0%) | 5/10 (50%) |
| Tamsulosin - Medium Dose Level (Steady State - PK Study) | — | 1/10 (10%) | 5/10 (50%) |
| Tamsulosin - High Dose Level (Steady State - PK Study) | — | 0/10 (0%) | 3/10 (30%) |
| Tamsulosin - Low Dose Level (Group D-Denovo) | — | 2/82 (2.4%) | 51/82 (62.2%) |
| Tamsulosin - Medium Dose Level (Group D-Denovo) | — | 3/61 (4.9%) | 25/61 (41%) |
| Tamsulosin - High Dose Level (Group D-Denovo) | — | 4/41 (9.8%) | 33/41 (80.5%) |
| Tamsulosin - Low Dose Level (Group D-527.51 Rollover) | — | 1/93 (1.1%) | 31/93 (33.3%) |
| Tamsulosin - Medium Dose Level (Group D-527.51 Rollover) | — | 1/41 (2.4%) | 10/41 (24.4%) |
| Tamsulosin - High Dose Level (Group D-527.51 Rollover) | — | 1/29 (3.4%) | 9/29 (31%) |
| Event | Tamsulosin - Low Dose Level (Steady State - PK Study) | Tamsulosin - Medium Dose Level (Steady State - PK Study) | Tamsulosin - High Dose Level (Steady State - PK Study) | Tamsulosin - Low Dose Level (Group D-Denovo) | Tamsulosin - Medium Dose Level (Group D-Denovo) | Tamsulosin - High Dose Level (Group D-Denovo) | Tamsulosin - Low Dose Level (Group D-527.51 Rollover) | Tamsulosin - Medium Dose Level (Group D-527.51 Rollover) | Tamsulosin - High Dose Level (Group D-527.51 Rollover) |
|---|---|---|---|---|---|---|---|---|---|
| Ventriculoperitoneal shunt malfunctionInjury, poisoning and procedural complications | 0/10 | 1/10 | 0/10 | 1/82 | 1/61 | 0/41 | 0/93 | 0/41 | 0/29 |
| Urinary tract infectionInfections and infestations | 0/10 | 0/10 | 0/10 | 0/82 | 0/61 | 2/41 | 0/93 | 1/41 | 1/29 |
| Tibial torsionCongenital, familial and genetic disorders | 0/10 | 0/10 | 0/10 | 0/82 | 0/61 | 1/41 | 0/93 | 0/41 | 0/29 |
| CellulitisInfections and infestations | 0/10 | 0/10 | 0/10 | 0/82 | 0/61 | 1/41 | 0/93 | 0/41 | 0/29 |
| GastroenteritisInfections and infestations | 0/10 | 0/10 | 0/10 | 0/82 | 0/61 | 0/41 | 0/93 | 1/41 | 0/29 |
| HydrocephalusNervous system disorders | 0/10 | 0/10 | 0/10 | 2/82 | 1/61 | 0/41 | 0/93 | 0/41 | 0/29 |
| Tethered cord syndromeNervous system disorders | 0/10 | 0/10 | 0/10 | 0/82 | 0/61 | 1/41 | 0/93 | 0/41 | 0/29 |
| Dengue feverInfections and infestations | 0/10 | 0/10 | 0/10 | 0/82 | 1/61 | 0/41 | 0/93 | 0/41 | 0/29 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/10 | 0/10 | 0/10 | 0/82 | 1/61 | 0/41 | 0/93 | 0/41 | 0/29 |
| Peritoneal cystGastrointestinal disorders | 0/10 | 0/10 | 0/10 | 1/82 | 0/61 | 0/41 | 0/93 | 0/41 | 0/29 |
| Event | Tamsulosin - Low Dose Level (Steady State - PK Study) | Tamsulosin - Medium Dose Level (Steady State - PK Study) | Tamsulosin - High Dose Level (Steady State - PK Study) | Tamsulosin - Low Dose Level (Group D-Denovo) | Tamsulosin - Medium Dose Level (Group D-Denovo) | Tamsulosin - High Dose Level (Group D-Denovo) | Tamsulosin - Low Dose Level (Group D-527.51 Rollover) | Tamsulosin - Medium Dose Level (Group D-527.51 Rollover) | Tamsulosin - High Dose Level (Group D-527.51 Rollover) |
|---|---|---|---|---|---|---|---|---|---|
| Urinary tract infectionInfections and infestations | 2/10 | 1/10 | 1/10 | 15/82 | 11/61 | 16/41 | 9/93 | 3/41 | 4/29 |
| PyrexiaGeneral disorders | 2/10 | 0/10 | 0/10 | 12/82 | 3/61 | 6/41 | 1/93 | 1/41 | 1/29 |
| RashSkin and subcutaneous tissue disorders | 0/10 | 2/10 | 0/10 | 1/82 | 2/61 | 0/41 | 0/93 | 1/41 | 0/29 |
| PharyngitisInfections and infestations | 0/10 | 0/10 | 0/10 | 11/82 | 1/61 | 2/41 | 2/93 | 1/41 | 1/29 |
| VomitingGastrointestinal disorders | 1/10 | 1/10 | 1/10 | 9/82 | 4/61 | 3/41 | 3/93 | 2/41 | 0/29 |
| Abdominal painGastrointestinal disorders | 0/10 | 0/10 | 1/10 | 4/82 | 0/61 | 1/41 | 2/93 | 0/41 | 1/29 |
| Abdominal pain upperGastrointestinal disorders | 1/10 | 0/10 | 0/10 | 3/82 | 1/61 | 1/41 | 2/93 | 0/41 | 0/29 |
| DiarrhoeaGastrointestinal disorders | 0/10 | 0/10 | 1/10 | 4/82 | 2/61 | 2/41 | 1/93 | 2/41 | 0/29 |
| Catheter related complicationGeneral disorders | 1/10 | 0/10 | 0/10 | 0/82 | 0/61 | 0/41 | 0/93 | 0/41 | 0/29 |
| MassGeneral disorders | 1/10 | 0/10 | 0/10 | 1/82 | 0/61 | 0/41 | 0/93 | 0/41 | 0/29 |
Treated Set: Includes all patients who are dispensed study medication and are documented to have taken at least one dose of treatment. In this study, some of the subjects are in multiple phases: PK and Group D-Denovo. Thus, the baseline characteristics are based on the unique subject entered into the study.
| Age, Continuous(years) | Tamsulosin - Low Dose Level (PK Study) | Tamsulosin - Medium Dose Level (PK Study) | Tamsulosin - High Dose Level (PK Study) | Tamsulosin - Low Dose Level (Group D-Denovo) | Tamsulosin - Medium Dose Level (Group D-Denovo) | Tamsulosin - High Dose Level (Group D-Denovo) | Tamsulosin - Low Dose Level (Group D-527.51 Rollover) | Tamsulosin - Medium Dose Level (Group D-527.51 Rollover) | Tamsulosin - High Dose Level (Group D-527.51 Rollover) | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 8.7 ± 4.5 | 6.5 ± 2.6 | 8.8 ± 3.7 | 6.8 ± 3.4 | 6.3 ± 3.7 | 8.1 ± 3.8 | 8.1 ± 3.8 | 7.0 ± 3.4 | 8.3 ± 4.1 | 7.7 ± 3.7 |
| Sex: Female, Male(Participants) | Tamsulosin - Low Dose Level (PK Study) | Tamsulosin - Medium Dose Level (PK Study) | Tamsulosin - High Dose Level (PK Study) | Tamsulosin - Low Dose Level (Group D-Denovo) | Tamsulosin - Medium Dose Level (Group D-Denovo) | Tamsulosin - High Dose Level (Group D-Denovo) | Tamsulosin - Low Dose Level (Group D-527.51 Rollover) | Tamsulosin - Medium Dose Level (Group D-527.51 Rollover) | Tamsulosin - High Dose Level (Group D-527.51 Rollover) | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Female | 5 | 3 | 5 | 12 | 7 | 10 | 21 | 8 | 12 | 83 |
| Male | 5 | 7 | 5 | 10 | 9 | 9 | 33 | 5 | 17 | 100 |
The record gives a start of Apr 2006, a primary completion of Jun 2009 and a completion of Jun 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2016, 6 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tamsulosin